Radius Recycling 10-Q 1 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 31, 2018
Document and Entity Information
Entity Registrant Name	Radius Health, Inc.
Entity Central Index Key	1,428,522
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		45,539,516
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 62,014	$ 118,564
Restricted cash	558	55
Marketable securities	172,120	134,714
Accounts receivable, net	12,908	4,441
Inventory	5,546	4,366
Prepaid expenses	10,097	5,175
Other current assets	1,193	2,191
Total current assets	264,436	269,506
Investments	42,235	176,978
Property and equipment, net	4,561	6,195
Intangible assets	7,581	8,180
Other assets	589	799
Total assets	319,402	461,658
Current liabilities:
Accounts payable	6,294	3,915
Accrued expenses and other current liabilities	41,759	49,512
Total current liabilities	48,053	53,427
Other non-current liabilities	118	189
Notes payable	176,180	166,006
Total liabilities	224,351	219,622
Commitments and contingencies
Stockholders’ equity:
Common stock, $.0001 par value; 200,000,000 shares authorized, 45,539,516 shares and 44,616,586 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	5	4
Additional paid-in-capital	1,158,417	1,124,630
Accumulated other comprehensive loss	(848)	(314)
Accumulated deficit	(1,062,523)	(882,284)
Total stockholders’ equity	95,051	242,036
Total liabilities and stockholders’ equity	$ 319,402	$ 461,658

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	45,476,455	44,616,586
Common stock, shares outstanding (in shares)	45,476,455	44,616,586

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
OPERATING EXPENSES:
Cost of sales - intangible amortization	$ 200	$ 200	$ 599	$ 200
Research and development	26,804	20,997	75,979	60,176
Selling, general and administrative	43,661	47,723	140,266	135,943
Other operating expenses	0	0	10,801	0
Loss from operations	(45,219)	(55,704)	(167,714)	(182,228)
OTHER (EXPENSE) INCOME:
Other income (expense)	17	(195)	83	(212)
Interest expense	(5,793)	(2,763)	(17,041)	(2,763)
Interest income	1,193	819	4,433	1,983
NET LOSS	(49,802)	(57,843)	(180,239)	(183,220)
OTHER COMPREHENSIVE LOSS:
Unrealized gain (loss) from available-for-sale debt securities	442	(1)	(534)	(70)
COMPREHENSIVE LOSS	(49,360)	(57,844)	(180,773)	(183,290)
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC AND DILUTED	$ (49,802)	$ (57,843)	$ (180,239)	$ (183,220)
LOSS PER SHARE:
Basic and diluted (in dollars per share)	$ (1.09)	$ (1.31)	$ (3.98)	$ (4.21)
WEIGHTED AVERAGE SHARES:
Basic and diluted (in shares)	45,498,909	43,999,451	45,291,176	43,535,874
Product
REVENUES:
Product revenue, net	$ 27,639	$ 3,469	$ 64,815	$ 4,449
OPERATING EXPENSES:
Cost of sales - product	2,193	253	4,884	358
License
REVENUES:
Product revenue, net	$ 0	$ 10,000	$ 0	$ 10,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS USED IN OPERATING ACTIVITIES:
Net loss	$ (180,239)	$ (183,220)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,005	1,385
Amortization of discount on marketable securities, net	(199)	(100)
Amortization of debt discount and debt issuance costs	10,174	1,568
Stock-based compensation	22,270	28,785
Changes in operating assets and liabilities:
Inventory	(1,180)	(3,074)
Accounts receivable, net	(8,467)	(11,682)
Other current assets	(4,922)	(5,493)
Increase (Decrease) in Other Current Assets	(998)	0
Other long-term assets	210	(7)
Accounts payable	2,379	(2,414)
Accrued expenses and other current liabilities	(7,455)	7,327
Other non-current liabilities	(71)	(166)
Net cash used in operating activities	(164,497)	(167,091)
CASH FLOWS PROVIDED BY INVESTING ACTIVITIES:
Purchases of property and equipment	(70)	(2,950)
Payments for capitalized milestones	0	(8,712)
Purchases of marketable securities	(499)	(117,441)
Sales and maturities of marketable securities	97,501	170,208
Net cash provided by investing activities	96,932	41,105
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:
Proceeds from exercise of stock options and warrant exercises	8,953	16,167
Proceeds from issuance of convertible debt	0	305,000
Payment of debt issuance costs	0	(9,360)
Proceeds from issuance of shares under employee stock purchase plan	2,565	2,550
Net cash provided by financing activities	11,518	314,357
NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(56,047)	188,371
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT BEGINNING OF YEAR	118,619	258,614
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF PERIOD	62,572	446,985
SUPPLEMENTAL DISCLOSURES:
Cash paid for income taxes	22	26
Property and equipment purchases in accrued expenses at period end	$ 298	$ 487

Organization

Organization	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Radius Health, Inc. (“Radius” or the “Company”) is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. In April 2017, the Company's first commercial product, TYMLOS ® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In April 2018, the Company submitted a request for re-examination of the negative opinion adopted by the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) on the Company’s European Marketing Authorisation Application (“MAA”) for abaloparatide for subcutaneous administration (“abaloparatide-SC”) and in July 2018, following a re-examination procedure, the CHMP maintained its negative opinion. The Company's clinical pipeline includes an investigational abaloparatide transdermal patch (“abaloparatide-patch”) for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug elacestrant (RAD1901), a selective estrogen receptor degrader for potential use in the treatment of hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator for potential use in the treatment of hormone-receptor positive breast cancer. The Company is subject to the risks associated with biopharmaceutical companies with a limited operating history, including dependence on key individuals, a developing business model, the necessity of securing regulatory approvals to market its investigational product candidates, market acceptance and the successful commercialization of TYMLOS, or any of the Company’s investigational product candidates following receipt of regulatory approval, competition for TYMLOS or any of the Company's investigational product candidates following receipt of regulatory approval, and the continued ability to obtain adequate financing to fund the Company’s future operations. The Company has incurred losses and expects to continue to incur additional losses for the foreseeable future. As of September 30, 2018 , the Company had an accumulated deficit of $ 1,062.5 million, and total cash, cash equivalents, restricted cash, marketable securities, and investments of $ 276.9 million . Based upon its cash, cash equivalents, marketable securities, and investments as of September 30, 2018 , the Company believes that, prior to the consideration of potential proceeds from partnering and/or collaboration activities, it has sufficient capital to fund its development plans, U.S. commercial activities and other operational activities for at least twelve months from the date of this filing. The Company expects to finance its commercial activities in the United States and development costs of its clinical product portfolio with its existing cash and cash equivalents, marketable securities and investments, as well as future product sales or through strategic financing opportunities that could include, but are not limited to, partnering or other collaboration agreements, future offerings of its equity, royalty based financing arrangements, or the incurrence of debt or other alternative financing arrangements which may include a combination of the foregoing. However, there is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company fails to obtain additional capital, it may be unable to conduct its ongoing commercialization activities or complete its planned preclinical studies and clinical trials and obtain approval of certain of its investigational product candidates from the FDA or foreign regulatory authorities.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies Basis of Presentation —The accompanying unaudited condensed consolidated financial statements and the related disclosures of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with U.S. GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2018 . Subsequent events have been evaluated up to the date of issuance of these financial statements. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on March 1, 2018. Certain prior period amounts have been reclassified to conform to the current period presentation. Significant Accounting Policies —The significant accounting policies identified in the Company’s 2017 Form 10-K that require the Company to make estimates and assumptions include: revenue recognition, inventory obsolescence, long-lived assets and intangible assets, accounting for stock-based compensation, contingencies, tax valuation reserves, fair value measures, and accrued expenses. There were no changes to significant accounting policies during the nine months ended September 30, 2018 , except for the adoption of three Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”), which are detailed below. Accounting Standards Updates, Recently Adopted— In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted this ASU as of January 1, 2018 and it did not have a material impact on its condensed consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash (“ASU 2016-18”). The amendments in this update require that amounts generally described as restricted cash and restricted cash equivalents be included within cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 became effective January 1, 2018. As a result of adopting ASU 2016-18, the Company includes its restricted cash balance in the cash and cash equivalents reconciliation of operating, investing and financing activities. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows. As of As of September 30, 2018 September 30, 2017 Cash and cash equivalents $ 62,014 $ 446,938 Restricted cash 558 47 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 62,572 $ 446,985 In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). ASU 2017-09 provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. The amendments in ASU 2017-09 are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted, applied prospectively to an award modified on or after the adoption date. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered non-substantive. The Company adopted this ASU as of January 1, 2018 and it did not have a material impact on its condensed consolidated financial statements. Accounting Standards Updates, Recently Issued— In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 amends the FASB Accounting Standards Codification (“ASC”) to expand the scope of FASB ASC Topic 718, Compensation-Stock Compensation , to include accounting for share-based payment transactions for acquiring goods and services from non-employees. The amendments in ASU 2018-07 are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. Early adoption is permitted. The Company is currently assessing the potential impact of adopting ASU 2018-07 on its financial statements and related disclosures In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 supersedes the lease guidance under FASB ASC Topic 840, Leases , resulting in the creation of FASB ASC Topic 842, Leases . ASU 2016-02 requires a lessee to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases (“ASU 2018-10”) and ASU No. 2018-11, Target Improvements to Topic 842, Leases (“ASU 2018-11”). The amendments in ASU 2018-10 provide additional clarification and implementation guidance on certain aspects of ASU 2016-02 and have the same effective and transition requirements as ASU 2016-02. ASU 2018-11 gives entities the option to not provide comparative period financial statements and instead apply the transition requirements as of the effective date of the new standard. ASU 2016-02, ASU 2018-10 and ASU 2018-11 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company plans to adopt the new standard using the optional method under ASU 2018-11 and is currently working through lease contract scoping, design and implementation of transition related controls, and finalization of accounting elections. The Company is still assessing the impact that this standard will have on its condensed consolidated financial statements and related disclosures; however, it anticipates that the new standard will result in the Company recording additional right of use assets and corresponding liabilities on its consolidated balance sheet. In July 2018, the FASB issued ASU 2018-09, Codification Improvements , or (“ASU 2018-09”). This amendment makes changes to a variety of topics to clarify, correct errors in, or make minor improvements to the ASC. The majority of the amendments in ASU 2018-09 will be effective for the Company in annual periods beginning after December 15, 2018. The Company is currently evaluating the effects the adoption of ASU 2018-09 will have on its consolidated financial statements, results of operations and cash flows. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement - Disclosure Framework-Changes to the Disclosure Requirement for Fair Value Measurement , or (“ASU 2018-13”). The amendments in this ASU 2018-13 modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendment under ASU 2018-13 are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the effects the adoption of ASU 2018-13 will have on its consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40 (“ASU 2018-15”). ASU 2018-15 updates guidance regarding accounting for a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. The Company does not expect the adoption of ASU 2018-15 to have a material impact on its results of operations, financial position or cash flows. On August 17, 2018, the SEC issued an amendment to Rule 3-04 of Regulation S-X, which extended the annual disclosure requirement of reporting changes in stockholders’ equity to interim periods. Such disclosures are to be provided in a note to the financial statements or in a separate financial statement and requires both the year-to-date information and subtotals for each interim period. On September 25, 2018, the SEC issued guidance under a Compliance and Disclosure Interpretation (C&DI 105.09) to clarify the effective date of the requirement. Under the guidance in C&DI 105.09, the Company plans to implement this updated disclosure requirement beginning with the first quarter 2019 Form 10-Q.

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities Available-for-sale marketable securities and cash and cash equivalents as of September 30, 2018 and December 31, 2017 consist of the following (in thousands): September 30, 2018 Amortized Cost Value Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 15,236 $ — $ — $ 15,236 Money market funds 46,778 — — 46,778 Total $ 62,014 $ — $ — $ 62,014 Marketable securities: Domestic corporate debt securities $ 155,346 $ — $ (643 ) $ 154,703 Agency bonds 59,981 — (329 ) 59,652 Total $ 215,327 $ — $ (972 ) $ 214,355 December 31, 2017 Amortized Cost Value Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 73,302 $ — $ — $ 73,302 Money market funds 325 — — 325 Domestic corporate commercial paper 44,937 — — 44,937 Total $ 118,564 $ — $ — $ 118,564 Marketable securities: Domestic corporate debt securities $ 207,320 $ 1 $ (235 ) $ 207,086 Domestic corporate commercial paper 29,844 — (7 ) 29,837 Agency bonds 74,842 — (73 ) 74,769 Total $ 312,006 $ 1 $ (315 ) $ 311,692 There were no available-for-sale marketable securities that had been in an unrealized loss position for more than 12 months as of September 30, 2018 or December 31, 2017 , respectively. There were 29 marketable securities with an aggregate fair value of $214.4 million in an unrealized loss position for less than 12 months as of September 30, 2018 . There were 38 marketable securities with an aggregate fair value of $299.2 million in an unrealized loss position for less than 12 months as of December 31, 2017 . The Company considered the decrease in market value for these securities to be primarily attributable to current economic conditions. As it was not more likely than not that the Company would be required to sell these securities before the recovery of their amortized cost basis, which may be at maturity, the Company did not consider these investments to be other-than-temporarily impaired as of September 30, 2018 . As of September 30, 2018 , the aggregate fair value of marketable securities maturing within one year and after one year through two years was $172.1 million and $42.2 million , respectively.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company determines the fair value of its financial instruments based upon the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Below are the three levels of inputs that may be used to measure fair value: • Level 1—Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Transfers into or out of any hierarchy level are recognized at the end of the reporting period in which the transfers occurred. There were no material transfers between any levels during the nine months ended September 30, 2018 . There were no material transfers between any levels during 2017. The following table summarizes the financial instruments measured at fair value on a recurring basis in the Company’s accompanying condensed consolidated balance sheets as of September 30, 2018 and December 31, 2017 (in thousands): As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Cash $ 15,236 $ — $ — $ 15,236 Money market funds (1) 46,778 — — 46,778 Total $ 62,014 $ — $ — $ 62,014 Marketable Securities Domestic corporate debt securities (2) $ — $ 154,703 $ — $ 154,703 Agency bonds (2) — 59,652 — 59,652 Total $ — $ 214,355 $ — $ 214,355 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Cash $ 73,302 $ — $ — $ 73,302 Money market funds (1) 325 — — 325 Domestic corporate commercial paper (2) — 44,937 — 44,937 Total $ 73,627 $ 44,937 $ — $ 118,564 Marketable Securities Domestic corporate debt securities (2) $ — $ 207,086 $ — $ 207,086 Domestic corporate commercial paper (2) — 29,837 — 29,837 Agency bonds (2) — 74,769 — 74,769 Total $ — $ 311,692 $ — $ 311,692 (1) Fair value is based upon quoted market prices. (2) Fair value is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources, including market participants, dealers and brokers.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consisted of the following at September 30, 2018 and December 31, 2017 (in thousands): September 30, December 31, Raw materials $ 4,257 $ 3,852 Work in process 636 313 Finished goods 653 201 Total inventories $ 5,546 $ 4,366 Inventory acquired prior to receipt of the marketing approval for TYMLOS, totaling approximately $1.6 million , was expensed as research and development expense as incurred. The Company began to capitalize the costs associated with the production of TYMLOS upon receipt of FDA approval on April 28, 2017. Finished goods manufactured by the Company have a 36 -month shelf life from date of manufacture.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets The following table presents intangible assets as of September 30, 2018 (in thousands): September 30, Estimated useful life Acquired and in-licensed rights $ 8,712 11 Years Less: accumulated amortization (1,131 ) Total intangible asset, net $ 7,581 Acquired and in-licensed rights as of September 30, 2018 consist of the €8.0 million (approximately $8.7 million on the date paid) milestone paid to Ipsen, which was triggered by FDA approval of TYMLOS on April 28, 2017. The Company recorded approximately $0.2 million and $0.6 million in amortization expense related to intangible assets, using the straight-line methodology, which is considered the best estimate of economic benefit, during the three and nine months ended September 30, 2018 . Estimated future amortization expense for intangible assets as of September 30, 2018 is approximately $0.2 million for the remainder of 2018 , and approximately $0.8 million per year over the remaining life.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following for the periods set forth below (in thousands): September 30, December 31, Commercial costs and product revenue reserves $ 13,567 $ 14,300 Research and development costs 11,212 8,406 Payroll and employee benefits 11,619 16,934 Interest 763 3,482 Restructuring costs 628 — Professional fees 3,875 6,295 Other current liabilities 95 95 Total accrued expenses and other current liabilities $ 41,759 $ 49,512

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Convertible Notes Payable	Convertible Notes Payable On August 14, 2017, in a registered underwritten public offering, the Company issued $300 million aggregate principal amount of 3% Convertible Senior Notes due September 1, 2024 (the “Convertible Notes”). In addition, on September 12, 2017, the Company issued an additional $5.0 million principal amount of Convertible Notes pursuant to the exercise of an over-allotment option granted to the underwriters in the offering. In accordance with accounting guidance for debt with conversion and other options, the Company separately accounted for the liability component (“Liability Component”) and embedded conversion option (the “Equity Component”) of the Convertible Notes by allocating the proceeds between the Liability Component and the Equity Component, due to the Company’s ability to settle the Convertible Notes in cash, common stock or a combination of cash and common stock, at its option. In connection with the issuance of the Convertible Notes, the Company incurred approximately $9.4 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs to the Liability and Equity Components based on the allocation of the proceeds. Of the total $9.4 million of debt issuance costs, $4.3 million was allocated to the Equity Component and recorded as a reduction to additional paid-in capital and $5.1 million was allocated to the liability component and is now recorded as a reduction of the Convertible Notes in the Company’s condensed consolidated balance sheet. The portion allocated to the liability component is amortized to interest expense using the effective interest method over seven years. The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 3.00% per annum, payable semi-annually in arrears on March 1 and September 1, beginning on March 1, 2018. Upon conversion, the Convertible Notes will be convertible into cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election. Prior to December 31, 2017, the Convertible Notes were not convertible except in connection with a make whole fundamental change, as defined in the respective indentures. The Convertible Notes will be subject to redemption at the Company’s option, on or after September 1, 2021, in whole or in part, if the conditions described below are satisfied. The Convertible Notes will mature on September 1, 2024, unless earlier converted, redeemed or repurchased in accordance with their terms. Subject to satisfaction of certain conditions and during the periods described below, the Convertible Notes may be converted at an initial conversion rate of 20.4891 shares of common stock per $1,000 principal amount of the Convertible Notes (equivalent to an initial conversion price of approximately $48.81 per share of common stock). Holders of the Convertible Notes may convert all or any portion of their notes, in multiples of $1,000 principal amount, at their option at any time prior to the close of business on the business day immediately preceding June 1, 2024 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2017 (and only during such calendar quarter), if the last reported sale price of the Company's common stock for at least 20 trading days (whether consecutive or not) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five -business day period after any five -consecutive trading day period (the “measurement period”) in which the “trading price” per $1,000 principal amount of the Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls the Convertible Notes for redemption, until the close of business on the business day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. As of September 30, 2018 , none of the above circumstances had occurred and as such, the Convertible Notes may not be converted. Prior to September 1, 2021, the Company may not redeem the Convertible Notes. On or after September 1, 2021, the Company may redeem for cash all or part of the Convertible Notes if the last reported sale price of the Company’s common stock equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 -consecutive trading day period ending within five trading days prior to the date on which the Company provides notice of the redemption. The redemption price will be the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. In addition, calling any Convertible Note for redemption will constitute a make-whole fundamental change with respect to that Convertible Note, in which case the conversion rate applicable to the conversion of that Convertible Note, if it is converted in connection with the redemption, will be increased in certain circumstances. The initial carrying amount of the Liability Component of $166.3 million was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected the Company's non-convertible debt borrowing rate for similar debt. The Equity Component of the Convertible Notes of $138.7 million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Convertible Notes of $305.0 million and the fair value of the Liability of the Convertible Notes of approximately $166.3 million on their respective dates of issuance. The excess of the principal amount of the Liability Component over its carrying amount (the “Debt Discount”) is amortized to interest expense using the effective interest method over seven years. The Equity Component is not remeasured as long as it continues to meet the conditions for equity classification. In connection with issuance of the Convertible Notes, the Company also incurred certain offering costs directly attributable to the offering. Such costs are deferred and amortized over the term of the debt to interest expense using the effective interest method. A portion of the deferred financing costs incurred in connection with the Convertible Notes was deemed to relate to the Equity Component and was allocated to additional paid-in capital. The outstanding balances of the Convertible Notes as of September 30, 2018 consisted of the following (in thousands): 2024 Convertible Notes Liability component: Principal $ 305,000 Less: debt discount and issuance costs, net $ (128,820 ) Net carrying amount $ 176,180 Equity component: $ 134,450 The Company determined the expected life of the Convertible Notes was equal to its seven -year term. The effective interest rate on the Liability Components of the Convertible Notes for the period from the date of issuance through September 30, 2018 was 13.04% . As of September 30, 2018 , the “if-converted value” did not exceed the remaining principal amount of the Convertible Notes. The fair values of the Convertible Notes are based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments, and, therefore, the Convertible Notes are classified within Level 2 in the fair value hierarchy. The fair value of the Convertible Notes, which differs from their carrying value, is influenced by interest rates, the Company’s stock price and stock price volatility. The estimated fair value of the Convertible Notes as of September 30, 2018 was approximately $234.0 million . The following table sets forth total interest expense recognized related to the Convertible Notes during the three and nine months ended September 30, 2018 and 2017 (in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Contractual interest expense $ 2,287 $ 1,195 $ 6,863 $ 1,195 Amortization of debt discount 3,379 1,568 9,804 1,568 Amortization of debt issuance costs 127 — 370 — Total interest expense $ 5,793 $ 2,763 $ 17,037 $ 2,763 Future minimum payments on the Company's long-term debt as of September 30, 2018 are as follows (in thousands): Years ended December 31, Future Minimum Payments 2019 $ 9,150 2020 9,150 2021 9,150 2022 9,150 2023 9,150 2024 and Thereafter 314,150 Total minimum payments $ 359,900 Less: interest (54,900 ) Less: unamortized discount (128,820 ) Less: current portion — Long Term Debt $ 176,180

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Options A summary of stock option activity during the nine months ended September 30, 2018 is as follows (in thousands, except for per share amounts): Shares Weighted- Average Exercise Price (in dollars per share) Weighted- Average Contractual Life (in years) Aggregate Intrinsic Value Options outstanding at December 31, 2017 5,648 $ 37.71 Granted 1,388 34.43 Exercised (461 ) 16.14 Canceled (407 ) 42.53 Expired (409 ) 52.04 Options outstanding at September 30, 2018 5,759 $ 37.29 7.48 $ 5,728 Options exercisable at September 30, 2018 3,121 $ 36.56 6.38 $ 5,728 The weighted-average grant-date fair value per share of options granted during the three and nine months ended September 30, 2018 was $ 12.86 and $19.07 , respectively. As of September 30, 2018 , there was approximately $49.3 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.64 years. Restricted Stock Units A summary of RSU activity during the nine months ended September 30, 2018 is as follows (in thousands, except for per share amounts): RSUs Weighted- Average Grant Date Fair Value (in dollars per share) RSUs Outstanding at December 31, 2017 147 $ 36.69 Granted 221 37.83 Vested (24 ) 41.37 Forfeited (82 ) 37.37 RSUs Outstanding at September 30, 2018 262 $ 37.00 As of September 30, 2018 , there was approximately $7.3 million of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of approximately 2.84 years. Employee Stock Purchase Plan In September 2016, the Company initiated the first offering period under the Company's 2016 Employee Stock Purchase Plan (the “ESPP”), pursuant to which eligible employees may purchase shares of the Company’s common stock on the last day of each predetermined six -month offering period at 85% of the lower of the fair market value per share at the beginning or end of the applicable offering period. The offering periods run from March 1 through August 31 and from September 1 through February 28 (or February 29, in a leap year) of each year. As of September 30, 2018 , the Company had recorded a liability of $0.2 million related to its ESPP obligations. In accordance with the terms of its ESPP, the Company recorded stock-based compensation expense of $0.2 million and $0.6 million for the three and nine -month periods ended September 30, 2018 , respectively.

Product Revenue Reserves and Al

Product Revenue Reserves and Allowances	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Product Revenue Reserves and Allowances	Product Revenue Reserves and Allowances To date, the Company’s only source of product revenue has been from the U.S. sales of TYMLOS, which it began shipping to customers in May 2017. The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2018 and 2017 (in thousands): Chargebacks, Discounts, and Fees Government and other rebates Returns Total Beginning balance at December 31, 2017 $ 1,986 $ 1,231 $ 421 $ 3,638 Provision related to sales in the current year 9,750 15,350 229 25,329 Adjustments related to prior period sales (76 ) (106 ) (111 ) (293 ) Credits and payments made (8,971 ) (9,257 ) (236 ) (18,464 ) Ending balance at September 30, 2018 $ 2,689 $ 7,218 $ 303 $ 10,210 Beginning balance at December 31, 2016 $ — $ — $ — $ — Provision related to sales in the current year 688 459 296 1,443 Adjustments related to prior period sales — Credits and payments made — Ending balance at September 30, 2017 $ 688 $ 459 $ 296 $ 1,443 Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets. The total provision related to sales for 2018 of $25.3 million is comprised of $6.1 million , $8.6 million , and $10.6 million , respectively, for activity during the quarters ended March 31, June 30, and September 30, 2018 . The total adjustments related to prior period sales in 2018 of $293 thousand is comprised of $245 thousand , $(29) thousand , and $77 thousand , respectively, for the quarters ended March 31, June 30, and September 30, 2018 . The total credits and payments made for 2018 of $18.5 million is comprised of $3.0 million , $6.7 million , and $8.8 million , respectively, for activity during the quarters ended March 31, June 30, and September 30, 2018 .

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share for the periods set forth below is calculated as follows (in thousands, except share and per share amounts): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Numerator: Net loss $ (49,802 ) $ (57,843 ) $ (180,239 ) $ (183,220 ) Denominator: Weighted-average number of common shares used in loss per share - basic and diluted 45,498,909 43,999,451 45,291,176 43,535,874 Loss per share - basic and diluted $ (1.09 ) $ (1.31 ) $ (3.98 ) $ (4.21 ) The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive. For the three and nine months ended September 30, 2018 and 2017 , respectively, all the Company’s options to purchase common stock, warrants, and restricted stock units outstanding were assumed to be anti-dilutive as earnings attributable to common stockholders was in a loss position. Three and Nine Months Ended September 30, 2018 2017 Options to purchase common stock 5,759,140 6,233,398 Warrants 120,532 605,415 Restricted stock units 262,002 108,940 The Company has the option to settle the conversion obligation for the Convertible Notes in cash, shares or any combination of the two. As the Convertible Notes are not convertible as of September 30, 2018 , they are not participating securities and they will not have an impact on the calculation of basic earnings or loss per share. Based on the Company's net loss position, there is no impact on the calculation of dilutive loss per share during the three and nine -month periods ended September 30, 2018 and 2017 , respectively.

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreements	License Agreements 3M In February 2018, the Company entered into a Scale-Up And Commercial Supply Agreement (the “Supply Agreement”) with 3M Company and 3M Innovative Properties Company (collectively with 3M Company, “3M”), pursuant to which 3M has agreed to exclusively manufacture Phase 3 and global commercial supplies of an abaloparatide-coated transdermal patch product (“Product”) and associated applicator devices (“Applicator”). Under the Supply Agreement, 3M will manufacture Product and Applicator for the Company according to agreed-upon specifications in sufficient quantities to meet the Company’s projected supply requirements. 3M will manufacture commercial supplies of Product at unit prices that decrease with an increase in the quantity the Company orders. The Company will pay 3M a mid-to-low single-digit royalty on worldwide net sales of Product and reimburse 3M for certain capital expenditures incurred to establish commercial supply of Product. The Company is responsible for providing, at its expense, supplies of abaloparatide drug substance to be used in manufacturing Product. During the term of the Supply Agreement, 3M and the Company have agreed to work exclusively with each other with respect to the delivery of abaloparatide, parathyroid hormone (“PTH”), and/or PTH related proteins via active transdermal, intradermal, or microneedle technology. In October 2018, the Company committed to fund 3M's purchase of capital equipment totaling approximately $9.6 million in preparation for manufacturing Phase 3 and potential commercial supplies of Product. Milestone payments for the equipment are expected to be made between the fourth quarter of 2018 and the third quarter of 2020. The initial term of the Supply Agreement began on its effective date, February 27, 2018 , and will continue for five years after the first commercial sale of Product. The Supply Agreement then automatically renews for successive three -year terms, unless earlier terminated pursuant to its terms or upon either party’s notice of termination to the other 24 months prior to the end of the then-current term. The Supply Agreement may be terminated by either party upon an uncured material breach of its terms by the other party, or due to the other party’s bankruptcy, insolvency, or dissolution. The Company may terminate the Supply Agreement upon the occurrence of certain events, including for certain clinical, technical, or commercial reasons impacting Product, if it is unable to obtain U.S. regulatory approval for Product within a certain time period, or if it ceases development or commercialization of Product. 3M may terminate the Supply Agreement upon the occurrence of certain events, including if there are certain safety issues related to Product, if the Company is unable to obtain U.S. regulatory approval for Product within a certain time period, or if the Company fails to order Product for a certain period of time after commercial launch of the Product in the U.S. Upon certain events of termination, 3M is required to transfer the manufacturing processes for Product and Applicator to the Company or a mutually agreeable third party and continue supplying Product and Applicator for a period of time pursuant to the Company’s projected supply requirements. In June 2009, the Company entered into a Development and Clinical Supplies Agreement with 3M, as amended (the “Development Agreement”), under which Product and Applicator development activities occur and 3M has manufactured phase 1 and 2 clinical trial supplies on an exclusive basis. The term of the Development Agreement runs until June 2019 and then automatically renews for additional one -year terms, unless earlier terminated, until the earliest of (i) the expiration or termination of the Supply Agreement, (ii) the mutual written agreement of the parties, or (iii) prior written notice by either party to the other party at least ninety days prior to the end of the then-current term of the Development Agreement that such party declines to extend the term. Either party may terminate the agreement in the event of an uncured material breach by the other party. The Company pays 3M for services delivered pursuant to the agreement on a fee-for-service or a fee-for-deliverable basis as specified in the agreement. The Company has paid 3M approximately $24.0 million , in the aggregate, through September 30, 2018 with respect to services and deliverables delivered pursuant to the Development Agreement. Ipsen In September 2005, the Company entered into a license agreement (the “License Agreement”), as amended, with an affiliate of Ipsen Pharma SAS (“Ipsen”) under which the Company exclusively licensed certain Ipsen compound technology and related patents covering abaloparatide to research, develop, manufacture, and commercialize certain compounds and related products in all countries, except Japan (where the Company has an option to negotiate a co-promotion agreement for abaloparatide-SC) and France (where the Company’s commercialization rights were subject to certain co-marketing and co-promotion rights exercisable by Ipsen, provided that certain conditions included in the License Agreement were met). The Company believes that Ipsen's co-marketing and co-promotion rights in France have permanently expired. Ipsen also granted the Company an exclusive right and license under the Ipsen compound technology and related patents to make, and have made, compounds or products in Japan. Ipsen further granted the Company an exclusive right and license under certain Ipsen formulation technology and related patents solely for purposes of enabling the Company to develop, manufacture, and commercialize compounds and products covered by the compound technology license in all countries, except Japan and France (as discussed above). In consideration for these rights, to date, the Company has made nonrefundable, non-creditable payments in the aggregate of $13.0 million to Ipsen, including payment in recognition of certain milestones having been achieved through September 30, 2018 . The License Agreement provides for further payments upon the achievement of certain future regulatory and commercial milestones. Total additional milestone payments that could be payable under the agreement are €24.0 million (approximately $28.0 million ). In connection with the FDA's approval of TYMLOS in April 2017, the Company paid Ipsen a milestone of €8.0 million (approximately $8.7 million on the date paid) under the License Agreement, which the Company recorded as an intangible asset within the condensed consolidated balance sheet and will amortize over the remaining patent life or the estimated useful life of the underlying product. The agreement also provides that the Company will pay to Ipsen a fixed five percent royalty based on net sales of the product by the Company or its sublicensees on a country-by-country basis until the later of the last to expire of the licensed patents or for a period of 10 years after the first commercial sale in such country. The royalty expense was $1.4 million and $3.2 million for the three and nine months ended September 30, 2018 , respectively, and is included within cost of sales. The date of the last to expire of the abaloparatide patents licensed from or co-owned with Ipsen, barring any extension thereof, is expected to be March 26, 2028. If the Company sublicenses abaloparatide to a third party, then the agreement provides that the Company would pay Ipsen a percentage of certain payments received from such sublicensee (in lieu of milestone payments not achieved at the time of such sublicense). The applicable percentage is in the low double-digit range. In addition, if the Company or its sublicensees commercialize a product that includes a compound discovered by it based on or derived from confidential Ipsen know-how, then the agreement provides that the Company would pay to Ipsen a fixed low single-digit royalty on net sales of such product on a country-by-country basis until the later of the last to expire of licensed patents that cover such product or for a period of 10 years after the first commercial sale of such product in such country. The License Agreement expires on a country-by-country basis on the later of (1) the date the last remaining valid claim in the licensed patents expires in that country, or (2) a period of 10 years after the first commercial sale of the licensed products in such country, unless it is sooner terminated in accordance with its terms. Pursuant to a final decision in arbitration proceedings with Ipsen in connection with the License Agreement, the Company is obligated to pay Ipsen $5.0 million if abaloparatide receives marketing approval in Japan and a fixed mid single-digit royalty based on net sales of abaloparatide in Japan. Eisai Co. Ltd. In June 2006, the Company entered into a license agreement (the “Eisai Agreement”), with Eisai Co. Ltd. (“Eisai”). Under the Eisai Agreement, Eisai granted to the Company an exclusive right and license to research, develop, manufacture and commercialize elacestrant (RAD1901) and related products from Eisai in all countries, except Japan. In consideration for the rights to elacestrant, the Company paid Eisai an initial license fee of $0.5 million , which was expensed during 2006. In March 2015, the Company entered into an amendment to the Eisai Agreement (the “Eisai Amendment”) in which Eisai granted to the Company the exclusive right and license to research, develop, manufacture and commercialize elacestrant in Japan. In consideration for the rights to elacestrant in Japan, the Company paid Eisai an initial license fee of $0.4 million upon execution of the Eisai Amendment, which was recognized as research and development expense in 2015. The Eisai Agreement, as amended, also provides for additional payments of up to $22.3 million , payable upon the achievement of certain clinical and regulatory milestones. To date, the Company has paid Eisai approximately $1.0 million in connection with the achievement of certain milestones. Under the Eisai Agreement, as amended, should a product covered by the licensed technology be commercialized, the Company will be obligated to pay to Eisai royalties in a variable mid-single-digit range based on net sales of the product on a country-by-country basis. The royalty rate will be reduced, on a country-by-country basis, at such time as the last remaining valid claim in the licensed patents expires, lapses, or is invalidated and the product is not covered by data protection clauses. In addition, the royalty rate will be reduced, on a country-by-country basis, if, in addition to the conditions specified in the previous sentence, sales of lawful generic versions of such product account for more than a specified minimum percentage of the total sales of all products that contain the licensed compound during a calendar quarter. The latest licensed patent is expected to expire, barring any extension thereof, on August 18, 2026. The Eisai Agreement, as amended, also grants the Company the right to grant sublicenses with prior written approval from Eisai. If the Company sublicenses the licensed technology to a third party, the Company will be obligated to pay Eisai, in addition to the milestones referenced above, a fixed low double-digit percentage of certain fees received from such sublicensee and royalties in the low single-digit range based on net sales of the sublicensee. The Eisai Agreement expires on a country-by-country basis on the later of (1) the date the last remaining valid claim in the licensed patents expires, lapses or is invalidated in that country, the product is not covered by data protection clauses, and the sales of lawful generic versions of the product account for more than a specified percentage of the total sales of all pharmaceutical products containing the licensed compound in that country; or (2) a period of 10 years after the first commercial sale of the licensed products in such country, unless it is sooner terminated. Duke University In December 2017, the Company entered into a patent license agreement (the “Duke Agreement”) with Duke University (“Duke”). Under the Duke Agreement, the Company acquired an exclusive worldwide license to certain Duke patents associated with elacestrant related to the use of elacestrant in the treatment of breast cancer as a monotherapy and in a combination therapy (collectively the “Duke Patents”). In consideration for these rights, the Company incurred non-refundable, non-creditable obligations to pay Duke an aggregate of $1.3 million , which were expensed as research and development costs during 2017. The Duke Agreement provides for additional payments upon the achievement of certain regulatory and commercial milestones totaling up to $3.8 million . To date, the Company has paid Duke approximately $0.5 million in connection with the achievement of certain milestones. The agreement provides that the Company would pay Duke a fixed low single-digit royalty based on net sales of a licensed product, on a country-by-country basis, beginning in August 2029 and ending upon expiration of the last licensed patent rights to expire in a country. The latest licensed patent is expected to expire, barring any extension thereof, on October 10, 2034. If the Company sublicenses the Duke Patents to a third party, the agreement provides that the Company will pay Duke a percentage of certain payments received by it from such sublicensee(s). The applicable percentage is in the high single-digit range on certain payments received in excess of a pre-specified amount. The Duke Agreement may be terminated by either party upon an uncured material breach of the agreement by the other party. The Company may terminate the agreement upon 60 days written notice to Duke, if the Company suspends its manufacture, use and sale of the licensed products. Teijin Limited In July 2017, the Company entered into a license and development agreement (the “Teijin Agreement”) with Teijin Limited (“Teijin”) for abaloparatide-SC in Japan. Pursuant to the Teijin Agreement, the Company granted Teijin: (i) an exclusive payment-bearing license under certain of the Company’s intellectual property to develop and commercialize abaloparatide-SC in Japan, (ii) a non-exclusive payment-bearing license under certain of the Company’s intellectual property to manufacture abaloparatide-SC for commercial supply in Japan, (iii) a right of reference to certain of the Company’s regulatory data related to abaloparatide-SC for purposes of developing, manufacturing and commercializing abaloparatide-SC in Japan, (iv) a manufacture transfer package, upon Teijin’s request, consisting of information and the Company’s know-how that is necessary for the manufacture of active pharmaceutical ingredient and abaloparatide-SC, (v) a right to request that the Company manufacture (or arrange for a third party to manufacture) and supply (or arrange for a third party to supply) the active pharmaceutical ingredient for the clinical supply of abaloparatide-SC in sufficient quantities to enable Teijin to conduct its clinical trials in Japan, and (vi) a right to request that the Company arrange for Teijin to directly enter into commercial supply agreements with the Company's existing contract manufacturers on the same pricing terms and on substantially similar commercial terms to those set forth in the Company's existing agreements with such contract manufacturers. In consideration for these rights, the Company received an upfront payment of $10.0 million , and may receive further payments upon the achievement of certain regulatory and sales milestones, as well as a fixed low double-digit royalty based on net sales of abaloparatide-SC in Japan during the royalty term, as defined below. In addition, the Company has an option to negotiate a co-promotion agreement with Teijin for abaloparatide-SC in Japan upon commercialization. Pursuant to the Teijin Agreement, the parties may further collaborate on new indications for abaloparatide-SC, and the Company also maintains full global rights to its development program for abaloparatide-patch, which is not part of the Teijin Agreement. Unless earlier terminated, the Teijin Agreement expires on the later of the (i) date on which the use, sale or importation of abaloparatide-SC is no longer covered by a valid claim under the Company’s patent rights licensed to Teijin in Japan, (ii) expiration of marketing or data exclusivity for abaloparatide-SC in Japan, or (iii) 10th anniversary of the first commercial sale of abaloparatide-SC in Japan. Upon execution of the Teijin Agreement, the transaction price included only the $10.0 million up-front payment owed to the Company. The Company received this amount in October 2017. As referenced above, the Company may receive further payments upon the achievement of certain regulatory and sales milestones, totaling up to $40.0 million , as well as a fixed low double-digit royalty based on net sales of abaloparatide-SC in Japan during the royalty term.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company did not record a federal or state income tax provision or benefit for the three and nine months ended September 30, 2018 and 2017 due to the expected loss before income taxes to be incurred for the years ended December 31, 2018 and 2017 , as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets. On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”), which was enacted in December 2017. The Company has recognized the provisional tax impacts related to the revaluation of the deferred tax assets and liabilities and included these amounts in its consolidated financial statements for the year ended December 31, 2017. The ultimate impact may differ from these provisional amounts due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Reform Act. The accounting was completed when the Company's 2017 U.S. corporate income tax return was filed in October 2018.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation The Company may be subject to legal proceedings and claims which arise in the ordinary course of its business. In the Company's opinion, the ultimate resolution of these matters is not expected to have a material effect on its consolidated financial statements. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the consolidated financial statements not misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements. As of September 30, 2018, the Company was not party to any significant litigation. Manufacturing Agreements In June 2016, the Company entered into a Supply Agreement with Ypsomed AG (“Ypsomed”), pursuant to which Ypsomed agreed to supply commercial and clinical supplies of a disposable pen injection device customized for subcutaneous injection of abaloparatide, the active pharmaceutical ingredient (“API”) for TYMLOS. The Company agreed to purchase a minimum number of devices at prices per device that decrease with an increase in quantity supplied. In addition, the Company has made milestone payments for Ypsomed’s capital developments in connection with the initiation of the commercial supply of the device and paid a one-time capacity fee. All costs and payments under the agreement are delineated in Swiss Francs. The agreement has an initial term of three years, which began on June 1, 2017, after which it automatically renews for two -year terms unless either party terminates the agreement upon 18 months' notice prior to the end of the then-current term. The Company agreed to purchase the devices at prices that decrease based on the quantity ordered, subject to an annual increase by Ypsomed and to minimum annual quantity requirements over the initial three -year term of the agreement. The Company is required to purchase a minimum number of batches equal to approximately CHF 0.5 million (approximately $0.5 million ) per year and CHF 2.9 million (approximately $3.0 million ) in total, subject to any annual price adjustments, during the initial term. In June 2016, the Company entered into a Commercial Supply Agreement with Vetter Pharma International GmbH (“Vetter”), pursuant to which Vetter has agreed to formulate the finished abaloparatide-SC drug product containing abaloparatide API, to fill cartridges with the drug product, to assemble the pen delivery device, and to package the pen for commercial distribution. The Company agreed to purchase the cartridges and pens in specified batch sizes at a price per unit. For labeling and packaging services, the Company agreed to pay a per unit price dependent upon the number of pens loaded with cartridges that are labeled and packaged. These prices are subject to an annual price adjustment. The agreement has an initial term of five years, which began on January 1, 2016, after which, it automatically renews for two -year terms unless either party notifies the other party two years before the end of the then-current term that it does not intend to renew. In July 2016, the Company entered into a Manufacturing Services Agreement with Polypeptide Laboratories Holding AB (“PPL”), as successor-in-interest to Lonza Group Ltd., pursuant to which PPL agreed to manufacture the commercial and clinical supplies of the API for abaloparatide. The Company agreed to purchase the API in batches at a price per gram in euros, subject to an annual increase by PPL. The agreement has an initial term of six years, which began on June 28, 2016, after which, it automatically renews for three -year terms unless either party provides notice of non-renewal 24 months before the end of the then-current term. The Company is also required to purchase a minimum number of batches annually, equal to approximately €2.9 million (approximately $3.4 million ) per year and approximately €16.1 million (approximately $18.7 million ) in total, subject to any annual price adjustments, during the initial term. Restructuring In March 2018, the Company implemented a restructuring plan to consolidate operations into its two main offices in Waltham, Massachusetts and Wayne, Pennsylvania to achieve operational efficiencies. As part of that effort, the Company will shut down its Parsippany, New Jersey office. Costs incurred in connection with the restructuring comprise one-time benefits to employees who are involuntarily terminated, costs related to the early termination of contracts, and retention costs for certain employees who will continue to work remotely for the Company after the Parsippany office is closed. Employee termination and retention related costs are generally recognized ratably over the future service period and contract termination costs are generally recognized as of the cease-use date. During the nine months ended September 30, 2018 , the Company incurred $1.5 million of employee termination and retention costs, with related cash payments to be made through the first quarter of 2019. In June 2018, the Company implemented a restructuring plan designed to increase the impact and efficiency of its field sales by re-allocating commercial resources across certain territories. Costs incurred in connection with the restructuring comprise one-time benefits to employees who are involuntarily terminated. During the nine months ended September 30, 2018 , the Company incurred $0.5 million of employee termination costs, and made related cash payments in the third quarter of 2018.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation —The accompanying unaudited condensed consolidated financial statements and the related disclosures of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with U.S. GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2018 . Subsequent events have been evaluated up to the date of issuance of these financial statements. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on March 1, 2018. Certain prior period amounts have been reclassified to conform to the current period presentation. Significant Accounting Policies —The significant accounting policies identified in the Company’s 2017 Form 10-K that require the Company to make estimates and assumptions include: revenue recognition, inventory obsolescence, long-lived assets and intangible assets, accounting for stock-based compensation, contingencies, tax valuation reserves, fair value measures, and accrued expenses. There were no changes to significant accounting policies during the nine months ended September 30, 2018 , except for the adoption of three Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”), which are detailed below.
Accounting Standards Updates, Recently Adopted	Accounting Standards Updates, Recently Adopted— In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted this ASU as of January 1, 2018 and it did not have a material impact on its condensed consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash (“ASU 2016-18”). The amendments in this update require that amounts generally described as restricted cash and restricted cash equivalents be included within cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 became effective January 1, 2018. As a result of adopting ASU 2016-18, the Company includes its restricted cash balance in the cash and cash equivalents reconciliation of operating, investing and financing activities. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows. As of As of September 30, 2018 September 30, 2017 Cash and cash equivalents $ 62,014 $ 446,938 Restricted cash 558 47 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 62,572 $ 446,985 In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). ASU 2017-09 provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. The amendments in ASU 2017-09 are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted, applied prospectively to an award modified on or after the adoption date. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered non-substantive. The Company adopted this ASU as of January 1, 2018 and it did not have a material impact on its condensed consolidated financial statements. Accounting Standards Updates, Recently Issued— In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 amends the FASB Accounting Standards Codification (“ASC”) to expand the scope of FASB ASC Topic 718, Compensation-Stock Compensation , to include accounting for share-based payment transactions for acquiring goods and services from non-employees. The amendments in ASU 2018-07 are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. Early adoption is permitted. The Company is currently assessing the potential impact of adopting ASU 2018-07 on its financial statements and related disclosures In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 supersedes the lease guidance under FASB ASC Topic 840, Leases , resulting in the creation of FASB ASC Topic 842, Leases . ASU 2016-02 requires a lessee to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows. As of As of September 30, 2018 September 30, 2017 Cash and cash equivalents $ 62,014 $ 446,938 Restricted cash 558 47 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 62,572 $ 446,985

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]
Schedule of available-for-sale marketable securities and cash and cash equivalents	Available-for-sale marketable securities and cash and cash equivalents as of September 30, 2018 and December 31, 2017 consist of the following (in thousands): September 30, 2018 Amortized Cost Value Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 15,236 $ — $ — $ 15,236 Money market funds 46,778 — — 46,778 Total $ 62,014 $ — $ — $ 62,014 Marketable securities: Domestic corporate debt securities $ 155,346 $ — $ (643 ) $ 154,703 Agency bonds 59,981 — (329 ) 59,652 Total $ 215,327 $ — $ (972 ) $ 214,355 December 31, 2017 Amortized Cost Value Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 73,302 $ — $ — $ 73,302 Money market funds 325 — — 325 Domestic corporate commercial paper 44,937 — — 44,937 Total $ 118,564 $ — $ — $ 118,564 Marketable securities: Domestic corporate debt securities $ 207,320 $ 1 $ (235 ) $ 207,086 Domestic corporate commercial paper 29,844 — (7 ) 29,837 Agency bonds 74,842 — (73 ) 74,769 Total $ 312,006 $ 1 $ (315 ) $ 311,692

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Summary of financial instruments measured at fair value on a recurring basis	The following table summarizes the financial instruments measured at fair value on a recurring basis in the Company’s accompanying condensed consolidated balance sheets as of September 30, 2018 and December 31, 2017 (in thousands): As of September 30, 2018 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Cash $ 15,236 $ — $ — $ 15,236 Money market funds (1) 46,778 — — 46,778 Total $ 62,014 $ — $ — $ 62,014 Marketable Securities Domestic corporate debt securities (2) $ — $ 154,703 $ — $ 154,703 Agency bonds (2) — 59,652 — 59,652 Total $ — $ 214,355 $ — $ 214,355 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Cash $ 73,302 $ — $ — $ 73,302 Money market funds (1) 325 — — 325 Domestic corporate commercial paper (2) — 44,937 — 44,937 Total $ 73,627 $ 44,937 $ — $ 118,564 Marketable Securities Domestic corporate debt securities (2) $ — $ 207,086 $ — $ 207,086 Domestic corporate commercial paper (2) — 29,837 — 29,837 Agency bonds (2) — 74,769 — 74,769 Total $ — $ 311,692 $ — $ 311,692 (1) Fair value is based upon quoted market prices. (2) Fair value is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources, including market participants, dealers and brokers.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Schedule of inventory	Inventory consisted of the following at September 30, 2018 and December 31, 2017 (in thousands): September 30, December 31, Raw materials $ 4,257 $ 3,852 Work in process 636 313 Finished goods 653 201 Total inventories $ 5,546 $ 4,366

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	The following table presents intangible assets as of September 30, 2018 (in thousands): September 30, Estimated useful life Acquired and in-licensed rights $ 8,712 11 Years Less: accumulated amortization (1,131 ) Total intangible asset, net $ 7,581

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consisted of the following for the periods set forth below (in thousands): September 30, December 31, Commercial costs and product revenue reserves $ 13,567 $ 14,300 Research and development costs 11,212 8,406 Payroll and employee benefits 11,619 16,934 Interest 763 3,482 Restructuring costs 628 — Professional fees 3,875 6,295 Other current liabilities 95 95 Total accrued expenses and other current liabilities $ 41,759 $ 49,512

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of outstanding balances of convertible notes	The outstanding balances of the Convertible Notes as of September 30, 2018 consisted of the following (in thousands): 2024 Convertible Notes Liability component: Principal $ 305,000 Less: debt discount and issuance costs, net $ (128,820 ) Net carrying amount $ 176,180 Equity component: $ 134,450
Schedule of interest expense recognized related to convertible notes	The following table sets forth total interest expense recognized related to the Convertible Notes during the three and nine months ended September 30, 2018 and 2017 (in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Contractual interest expense $ 2,287 $ 1,195 $ 6,863 $ 1,195 Amortization of debt discount 3,379 1,568 9,804 1,568 Amortization of debt issuance costs 127 — 370 — Total interest expense $ 5,793 $ 2,763 $ 17,037 $ 2,763
Schedule of future minimum payments on long-term debt	Future minimum payments on the Company's long-term debt as of September 30, 2018 are as follows (in thousands): Years ended December 31, Future Minimum Payments 2019 $ 9,150 2020 9,150 2021 9,150 2022 9,150 2023 9,150 2024 and Thereafter 314,150 Total minimum payments $ 359,900 Less: interest (54,900 ) Less: unamortized discount (128,820 ) Less: current portion — Long Term Debt $ 176,180

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock option activity	A summary of stock option activity during the nine months ended September 30, 2018 is as follows (in thousands, except for per share amounts): Shares Weighted- Average Exercise Price (in dollars per share) Weighted- Average Contractual Life (in years) Aggregate Intrinsic Value Options outstanding at December 31, 2017 5,648 $ 37.71 Granted 1,388 34.43 Exercised (461 ) 16.14 Canceled (407 ) 42.53 Expired (409 ) 52.04 Options outstanding at September 30, 2018 5,759 $ 37.29 7.48 $ 5,728 Options exercisable at September 30, 2018 3,121 $ 36.56 6.38 $ 5,728
Summary of restricted stock units activity	A summary of RSU activity during the nine months ended September 30, 2018 is as follows (in thousands, except for per share amounts): RSUs Weighted- Average Grant Date Fair Value (in dollars per share) RSUs Outstanding at December 31, 2017 147 $ 36.69 Granted 221 37.83 Vested (24 ) 41.37 Forfeited (82 ) 37.37 RSUs Outstanding at September 30, 2018 262 $ 37.00

Product Revenue Reserves and _2

Product Revenue Reserves and Allowances (Tables)	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of product revenue allowance and reserve categories	The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2018 and 2017 (in thousands): Chargebacks, Discounts, and Fees Government and other rebates Returns Total Beginning balance at December 31, 2017 $ 1,986 $ 1,231 $ 421 $ 3,638 Provision related to sales in the current year 9,750 15,350 229 25,329 Adjustments related to prior period sales (76 ) (106 ) (111 ) (293 ) Credits and payments made (8,971 ) (9,257 ) (236 ) (18,464 ) Ending balance at September 30, 2018 $ 2,689 $ 7,218 $ 303 $ 10,210 Beginning balance at December 31, 2016 $ — $ — $ — $ — Provision related to sales in the current year 688 459 296 1,443 Adjustments related to prior period sales — Credits and payments made — Ending balance at September 30, 2017 $ 688 $ 459 $ 296 $ 1,443

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per share	Basic and diluted net loss per share for the periods set forth below is calculated as follows (in thousands, except share and per share amounts): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Numerator: Net loss $ (49,802 ) $ (57,843 ) $ (180,239 ) $ (183,220 ) Denominator: Weighted-average number of common shares used in loss per share - basic and diluted 45,498,909 43,999,451 45,291,176 43,535,874 Loss per share - basic and diluted $ (1.09 ) $ (1.31 ) $ (3.98 ) $ (4.21 )
Schedule of potentially dilutive securities excluded from the computation of diluted weighted-average shares outstanding	The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive. For the three and nine months ended September 30, 2018 and 2017 , respectively, all the Company’s options to purchase common stock, warrants, and restricted stock units outstanding were assumed to be anti-dilutive as earnings attributable to common stockholders was in a loss position. Three and Nine Months Ended September 30, 2018 2017 Options to purchase common stock 5,759,140 6,233,398 Warrants 120,532 605,415 Restricted stock units 262,002 108,940

Organization (Details)

Organization (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 1,062,523	$ 882,284
Cash, cash equivalents, marketable securities, and investments	$ 276,900
Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cash and cash equivalents, period to support operations	12 months

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Cash and cash equivalents	$ 62,014	$ 118,564	$ 446,938
Restricted cash	558		47
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 62,572	$ 118,619	$ 446,985	$ 258,614

Marketable Securities - Schedul

Marketable Securities - Schedule of Available-for-sale Marketable Securities and Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Cash and cash equivalents:
Cash and cash equivalents, Amortized Cost Value	$ 62,014	$ 118,564	$ 446,938
Cash and cash equivalents, Gross Unrealized Gains	0	0
Cash and cash equivalents, Gross Unrealized Losses	0	0
Cash and cash equivalents, Fair Value	62,014	118,564
Marketable securities:
Marketable securities, Amortized Cost Value	215,327	312,006
Marketable securities, Gross Unrealized Gains	0	1
Marketable securities, Gross Unrealized Losses	(972)	(315)
Marketable securities, Fair Value	214,355	311,692
Domestic corporate debt securities
Marketable securities:
Marketable securities, Amortized Cost Value	155,346	207,320
Marketable securities, Gross Unrealized Gains	0	1
Marketable securities, Gross Unrealized Losses	(643)	(235)
Marketable securities, Fair Value	154,703	207,086
Domestic corporate commercial paper
Marketable securities:
Marketable securities, Amortized Cost Value		29,844
Marketable securities, Gross Unrealized Gains		0
Marketable securities, Gross Unrealized Losses		(7)
Marketable securities, Fair Value		29,837
Agency bonds
Marketable securities:
Marketable securities, Amortized Cost Value	59,981	74,842
Marketable securities, Gross Unrealized Gains	0	0
Marketable securities, Gross Unrealized Losses	(329)	(73)
Marketable securities, Fair Value	59,652	74,769
Cash
Cash and cash equivalents:
Cash and cash equivalents, Amortized Cost Value	15,236	73,302
Cash and cash equivalents, Gross Unrealized Gains	0	0
Cash and cash equivalents, Gross Unrealized Losses	0	0
Cash and cash equivalents, Fair Value	15,236	73,302
Money market funds
Cash and cash equivalents:
Cash and cash equivalents, Amortized Cost Value	46,778	325
Cash and cash equivalents, Gross Unrealized Gains	0	0
Cash and cash equivalents, Gross Unrealized Losses	0	0
Cash and cash equivalents, Fair Value	$ 46,778	325
Domestic corporate commercial paper
Cash and cash equivalents:
Cash and cash equivalents, Amortized Cost Value		44,937
Cash and cash equivalents, Gross Unrealized Gains		0
Cash and cash equivalents, Gross Unrealized Losses		0
Cash and cash equivalents, Fair Value		$ 44,937

Marketable Securities - Narrati

Marketable Securities - Narrative (Details) $ in Millions	Sep. 30, 2018USD ($)security	Dec. 31, 2017USD ($)security
Investments, Debt and Equity Securities [Abstract]
Debt securities held in an unrealized loss position for more than 12 months | security	0	0
Debt securities held in an unrealized loss position for less than 12 months | security	29	38
Fair value of debt securities in an unrealized loss position for less than 12 months	$ 214.4	$ 299.2
Aggregate fair value of marketable securities maturing within one year	172.1
Aggregate fair value of marketable securities maturing after one year through two years	$ 42.2

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 62,014	$ 118,564
Cash
Assets
Cash and cash equivalents	15,236	73,302
Money market funds
Assets
Cash and cash equivalents	46,778	325
Domestic corporate commercial paper
Assets
Cash and cash equivalents		44,937
Recurring basis
Assets
Cash and cash equivalents	62,014	118,564
Marketable Securities	214,355	311,692
Recurring basis | Domestic corporate debt securities
Assets
Marketable Securities	154,703	207,086
Recurring basis | Domestic corporate commercial paper
Assets
Marketable Securities		29,837
Recurring basis | Agency bonds
Assets
Marketable Securities	59,652	74,769
Recurring basis | Cash
Assets
Cash and cash equivalents	15,236	73,302
Recurring basis | Money market funds
Assets
Cash and cash equivalents	46,778	325
Recurring basis | Domestic corporate commercial paper
Assets
Cash and cash equivalents		44,937
Recurring basis | Level 1
Assets
Cash and cash equivalents	62,014	73,627
Marketable Securities	0	0
Recurring basis | Level 1 | Domestic corporate debt securities
Assets
Marketable Securities	0	0
Recurring basis | Level 1 | Domestic corporate commercial paper
Assets
Marketable Securities		0
Recurring basis | Level 1 | Agency bonds
Assets
Marketable Securities	0	0
Recurring basis | Level 1 | Cash
Assets
Cash and cash equivalents	15,236	73,302
Recurring basis | Level 1 | Money market funds
Assets
Cash and cash equivalents	46,778	325
Recurring basis | Level 1 | Domestic corporate commercial paper
Assets
Cash and cash equivalents		0
Recurring basis | Level 2
Assets
Cash and cash equivalents	0	44,937
Marketable Securities	214,355	311,692
Recurring basis | Level 2 | Domestic corporate debt securities
Assets
Marketable Securities	154,703	207,086
Recurring basis | Level 2 | Domestic corporate commercial paper
Assets
Marketable Securities		29,837
Recurring basis | Level 2 | Agency bonds
Assets
Marketable Securities	59,652	74,769
Recurring basis | Level 2 | Cash
Assets
Cash and cash equivalents	0	0
Recurring basis | Level 2 | Money market funds
Assets
Cash and cash equivalents	0	0
Recurring basis | Level 2 | Domestic corporate commercial paper
Assets
Cash and cash equivalents		44,937
Recurring basis | Level 3
Assets
Cash and cash equivalents	0	0
Marketable Securities	0	0
Recurring basis | Level 3 | Domestic corporate debt securities
Assets
Marketable Securities	0	0
Recurring basis | Level 3 | Domestic corporate commercial paper
Assets
Marketable Securities		0
Recurring basis | Level 3 | Agency bonds
Assets
Marketable Securities	0	0
Recurring basis | Level 3 | Cash
Assets
Cash and cash equivalents	0	0
Recurring basis | Level 3 | Money market funds
Assets
Cash and cash equivalents	$ 0	0
Recurring basis | Level 3 | Domestic corporate commercial paper
Assets
Cash and cash equivalents		$ 0

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	3 Months Ended		4 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Apr. 28, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 4,257			$ 4,257		$ 3,852
Work in process	636			636		313
Finished goods	653			653		201
Total inventories	5,546			5,546		$ 4,366
Research and development	$ 26,804	$ 20,997	$ 1,600	$ 75,979	$ 60,176
Finished goods shelf life				36 months

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets, Net [Abstract]
Acquired and in-licensed rights	$ 8,712
Less: accumulated amortization	(1,131)
Total intangible asset, net	$ 7,581	$ 8,180
Estimated useful life	11 years

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details) $ in Thousands, € in Millions	1 Months Ended		3 Months Ended	9 Months Ended
	Apr. 30, 2017USD ($)	Apr. 30, 2017EUR (€)	Sep. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2018EUR (€)	Sep. 30, 2017USD ($)
Finite-Lived Intangible Assets [Line Items]
Milestone payments that triggered intangible asset recognition				$ 0		$ 8,712
Amortization expense			$ 200	600
Estimated future amortization expense for intangible assets, remainder of year			200	200
Estimated future amortization expense for intangible assets, per year thereafter			$ 800	800
Collaborative Arrangement | Ipsen
Finite-Lived Intangible Assets [Line Items]
Milestone payments that triggered intangible asset recognition	$ 8,700	€ 8		$ 8,700	€ 8

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Commercial costs and product revenue reserves	$ 13,567	$ 14,300
Research and development costs	11,212	8,406
Payroll and employee benefits	11,619	16,934
Interest	763	3,482
Restructuring costs	628	0
Professional fees	3,875	6,295
Other current liabilities	95	95
Total accrued expenses and other current liabilities	$ 41,759	$ 49,512

Convertible Notes Payable - Nar

Convertible Notes Payable - Narrative (Details)	1 Months Ended
	Sep. 12, 2017USD ($)business_dayday$ / sharesshares	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Aug. 14, 2017USD ($)
Debt Instrument [Line Items]
Initial carrying amount		$ 176,180,000	$ 166,006,000
Convertible debt | 3.00% Convertible notes
Debt Instrument [Line Items]
Aggregate principal amount	$ 5,000,000			$ 300,000,000
Debt instrument stated rate	3.00%			3.00%
Debt issuance costs	$ 9,400,000
Debt instrument term	7 years
Debt conversion rate | shares	20.4891
Conversion ratio	0.0204891
Initial conversion price (in dollars per share) | $ / shares	$ 48.81
Initial carrying amount		176,180,000		$ 166,300,000
Equity component		134,450,000		138,700,000
Proceeds from the issuance of debt		$ 305,000,000		$ 305,000,000
Debt discount, remaining discount amortization period	7 years
Effective interest rate		13.04%
Estimated fair value		$ 234,000,000
Convertible debt | 3.00% Convertible notes | Stock price trigger at greater than or equal to 130%
Debt Instrument [Line Items]
Consecutive or non-consecutive trading days	20 days
Consecutive trading days | day	30
Percentage of stock price trigger	130.00%
Convertible debt | 3.00% Convertible notes | Stock price trigger less than 98%
Debt Instrument [Line Items]
Consecutive trading days | day	5
Percentage of stock price trigger	98.00%
Trading days | business_day	5
Convertible debt | 3.00% Convertible notes | Stock price trigger at greater than or equal to 130%, on or after September 1, 2021
Debt Instrument [Line Items]
Consecutive or non-consecutive trading days	20 days
Consecutive trading days | day	30
Percentage of stock price trigger	130.00%
Consecutive trading days, redemption notice period	5 days
Convertible debt | 3.00% Convertible notes | Additional paid-in capital
Debt Instrument [Line Items]
Debt issuance costs	$ 4,300,000
Convertible debt | 3.00% Convertible notes | Convertible notes
Debt Instrument [Line Items]
Debt issuance costs	$ 5,100,000

Convertible Notes Payable - Sum

Convertible Notes Payable - Summary of Outstanding Balances of Convertible Notes (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Aug. 14, 2017
Debt Instrument [Line Items]
Net carrying amount	$ 176,180	$ 166,006
Convertible debt | 3.00% Convertible notes
Debt Instrument [Line Items]
Principal	305,000		$ 305,000
Less: debt discount and issuance costs, net	(128,820)
Net carrying amount	176,180		166,300
Equity component	$ 134,450		$ 138,700

Convertible Notes Payable - S_2

Convertible Notes Payable - Summary of Total Interest Expense Recognized Related to the Convertible Notes (Details) - Convertible debt - 3.00% Convertible notes - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Debt Instrument [Line Items]
Contractual interest expense	$ 2,287	$ 1,195	$ 6,863	$ 1,195
Amortization of debt discount	3,379	1,568	9,804	1,568
Amortization of debt issuance costs	127	0	370	0
Total interest expense	$ 5,793	$ 2,763	$ 17,037	$ 2,763

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Future Minimum Payments on Long-Term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Aug. 14, 2017
Future Minimum Payments
Long Term Debt	$ 176,180	$ 166,006
Convertible debt | 3.00% Convertible notes
Future Minimum Payments
2,019	9,150
2,020	9,150
2,021	9,150
2,022	9,150
2,023	9,150
2024 and Thereafter	314,150
Total minimum payments	359,900
Less: interest	(54,900)
Less: unamortized discount	(128,820)
Less: current portion	0
Long Term Debt	$ 176,180		$ 166,300

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Options (Details) - Options to purchase common stock $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Shares
Options outstanding at beginning of period (in shares) | shares	5,648
Granted (in shares) | shares	1,388
Exercised (in shares) | shares	(461)
Canceled (in shares) | shares	(407)
Expired (in shares) | shares	(409)
Options outstanding at end of period (in shares) | shares	5,759
Options exercisable at end of period (in shares) | shares	3,121
Weighted- Average Exercise Price (in dollars per share)
Options outstanding at the beginning of the period (in dollars per share) | $ / shares	$ 37.71
Granted (in dollars per share) | $ / shares	34.43
Exercised (in dollars per share) | $ / shares	16.14
Canceled (in dollars per share) | $ / shares	42.53
Expired (in dollars per share) | $ / shares	52.04
Options outstanding at the end of the period (in dollars per share) | $ / shares	37.29
Options exercisable at the end of the period (in dollars per share) | $ / shares	$ 36.56
Weighted- Average Contractual Life (in years)
Options outstanding at the end of period	7 years 175 days
Options exercisable at the end of period	6 years 139 days
Aggregate Intrinsic Value
Options outstanding at the end of the period (in dollars) | $	$ 5,728
Options exercisable at the end of the period (in dollars) | $	$ 5,728

Stock Based Compensation - Stoc

Stock Based Compensation - Stock Options and Restricted Stock Units Narrative (Details) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2018USD ($)$ / shares	Sep. 30, 2018USD ($)$ / shares
Options to purchase common stock
Stock-based Compensation
Weighted-average grant-date fair value (in dollars per share) | $ / shares	$ 12.86	$ 19.07
Total unrecognized compensation expense	$ 49.3	$ 49.3
Weighted average period over which unrecognized compensation is expected to be recognized		2 years 234 days
RSUs
Stock-based Compensation
Total unrecognized compensation expense	$ 7.3	$ 7.3
Weighted average period over which unrecognized compensation is expected to be recognized		2 years 307 days

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Units (Details) - Restricted stock units (RSUs) shares in Thousands	9 Months Ended
	Sep. 30, 2018$ / sharesshares
RSUs
RSUs Outstanding at beginning of period (in shares) | shares	147
Granted (in shares) | shares	221
Vested (in shares) | shares	(24)
Forfeited (in shares) | shares	(82)
RSUs Outstanding at end of period (in shares) | shares	262
Weighted- Average Grant Date Fair Value (in dollars per share)
RSUs outstanding at the beginning of the period (in dollars per share) | $ / shares	$ 37
Granted (in dollars per share) | $ / shares	37.83
Exercised (in dollars per share) | $ / shares	41.37
Forfeited (in dollars per share) | $ / shares	37.37
RSUs outstanding at the end of the period (in dollars per share) | $ / shares	$ 36.69

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Stock Purchase Plan Narrative (Details) - Employee Stock Purchase Plan 2016 - USD ($) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2018	Sep. 30, 2018
Stock-based Compensation
Share-based compensation arrangement by share-based payment award, award vesting rights, offering period	6 months
Employee stock purchase plan, purchase price of common stock, percent	85.00%
Employee stock purchase plan obligation		$ 0.2	$ 0.2
Stock-based compensation expense		$ 0.2	$ 0.6

Product Revenue Reserves and _3

Product Revenue Reserves and Allowances (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2018	Sep. 30, 2017
Product Revenue Allowance and Reserves
Summary of Activity of Product Revenue Allowance and Reserves
Beginning balance			$ 3,638	$ 3,638	$ 0
Provision related to sales in the current year	$ 10,600	$ 8,600	6,100	25,329	1,443
Adjustments related to prior period sales	77	(29)	245	(293)	0
Credits and payments made	8,838	$ 6,745	2,981	(18,464)	0
Ending balance	10,210			10,210	1,443
Chargebacks, Discounts, and Fees
Summary of Activity of Product Revenue Allowance and Reserves
Beginning balance			1,986	1,986	0
Provision related to sales in the current year				9,750	688
Adjustments related to prior period sales				(76)
Credits and payments made				(8,971)
Ending balance	2,689			2,689	688
Government and other rebates
Summary of Activity of Product Revenue Allowance and Reserves
Beginning balance			1,231	1,231	0
Provision related to sales in the current year				15,350	459
Adjustments related to prior period sales				(106)
Credits and payments made				(9,257)
Ending balance	7,218			7,218	459
Returns
Summary of Activity of Product Revenue Allowance and Reserves
Beginning balance			$ 421	421	0
Provision related to sales in the current year				229	296
Adjustments related to prior period sales				(111)
Credits and payments made				(236)
Ending balance	$ 303			$ 303	$ 296

Product Revenue Reserves and _4

Product Revenue Reserves and Allowances Product Revenue Reserves and Allowances - Narrative (Details) - Product Revenue Allowance and Reserves - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2018	Sep. 30, 2017
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Provision related to sales in the current year	$ 10,600	$ 8,600	$ 6,100	$ 25,329	$ 1,443
Adjustments related to prior period sales	(77)	29	(245)	293	0
Credits and payments made	$ (8,838)	$ (6,745)	$ (2,981)	$ 18,464	$ 0

Net Loss Per Share - Basic and

Net Loss Per Share - Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Numerator:
Net loss	$ (49,802)	$ (57,843)	$ (180,239)	$ (183,220)
Denominator:
Weighted-average number of common shares used in loss per share - basic and diluted (in shares)	45,498,909	43,999,451	45,291,176	43,535,874
Loss per share - basic and diluted (in dollars per share)	$ (1.09)	$ (1.31)	$ (3.98)	$ (4.21)

Net Loss Per Share - Antidiluti

Net Loss Per Share - Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive (in shares)	5,759,140	6,233,398	5,728,531	7,468,544
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive (in shares)	120,532	605,415	120,533	605,415
Restricted stock units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive (in shares)	262,002	108,940	295,491	117,253

License Agreements (Details)

License Agreements (Details) € in Millions

Sep. 30, 2018USD ($)

Feb. 27, 2018

Oct. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Oct. 31, 2017USD ($)

Apr. 30, 2017USD ($)

Apr. 30, 2017EUR (€)

Mar. 31, 2015USD ($)

Jun. 30, 2009

Sep. 30, 2005USD ($)

Sep. 30, 2005EUR (€)

Sep. 30, 2018USD ($)

Sep. 30, 2017USD ($)

Apr. 28, 2017USD ($)

Dec. 31, 2006USD ($)

Sep. 30, 2018USD ($)

Sep. 30, 2018EUR (€)

Sep. 30, 2017USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2015USD ($)

Mar. 31, 2018USD ($)

Sep. 30, 2018USD ($)

Jun. 30, 2018USD ($)

Jul. 31, 2017USD ($)

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payments that triggered intangible asset recognition

$ 0

$ 8,712,000

Research and development

$ 26,804,000

$ 20,997,000

$ 1,600,000

75,979,000

$ 60,176,000

Eisai | License Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Period after the date of the first commercial sale of the product for license expiration

10 years

Initial license fee paid

$ 500,000

$ 400,000

Eisai | License Agreement | Maximum

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Payments to be made upon achievement of certain clinical and regulatory milestones

$ 22,300,000

Collaborative Arrangement | 3M Company

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Initial term

5 years

Renewal term

3 years

1 year

Termination period

24 months

90 days

Nonrefundable, non-creditable payment

$ 24,000,000

Collaborative Arrangement | Ipsen

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Nonrefundable, non-creditable payment

$ 13,000,000

Milestone payments that triggered intangible asset recognition

$ 8,700,000

€ 8

8,700,000

€ 8

Royalty rate (as a percent)

5.00%

5.00%

Royalty expense

$ 1,400,000

3,200,000

Collaborative Arrangement | Ipsen | Minimum

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Period after the date of the first commercial sale of the product for license expiration

10 years

10 years

Collaborative Arrangement | Ipsen | Maximum

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Additional payments to be made upon achievement of certain development and commercialization milestones

$ 28,000,000

€ 24

Collaborative Arrangement | Ipsen | License Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

License agreement, obligation to pay

$ 5,000,000

Collaborative Arrangement | Eisai

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Nonrefundable, non-creditable payment

$ 1,000,000

Collaborative Arrangement | Duke

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Termination period

60 days

Nonrefundable, non-creditable payment

$ 500,000

Additional payments to be made upon achievement of certain development and commercialization milestones

$ 3,800,000

Research and development

$ 1,300,000

Collaborative Arrangement | Teijin Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Aggregate amount if regulatory and sales milestones are achieved

$ 40,000,000

Collaborative Arrangement | Teijin Agreement | Maximum

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

License agreement, upfront payment received

$ 10,000,000

Scenario, Forecast | Collaborative Arrangement | 3M Company

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Collaborative Arrangement Funding to Purchase Capital Equipment

$ 9,600,000

Commitments and Contingencies -

Commitments and Contingencies - Manufacturing Agreements (Details) € in Millions, SFr in Millions, $ in Millions	1 Months Ended
	Jul. 31, 2016USD ($)	Jul. 31, 2016EUR (€)	Jun. 30, 2016CHF (SFr)	Jun. 30, 2016USD ($)
Ypsomed Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Services agreement, term			3 years	3 years
Services agreement, renewal term			2 years	2 years
Service agreement, period required for notice of non-renewal			18 months	18 months
Annual minimum batches			SFr 0.5	$ 0.5
Total minimum payments inclusive of milestone payments and one-time capacity fee			SFr 2.9	$ 3
Vetter Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Services agreement, term			5 years	5 years
Services agreement, renewal term			2 years	2 years
Service agreement, period required for notice of non-renewal			2 years	2 years
Lonza Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Services agreement, term	6 years	6 years
Services agreement, renewal term	3 years	3 years
Service agreement, period required for notice of non-renewal	24 months	24 months
Annual minimum batches	$ 3.4	€ 2.9
Total minimum payments inclusive of milestone payments and one-time capacity fee	$ 18.7	€ 16.1

Commitments and Contingencies_2

Commitments and Contingencies - Restructuring (Details) $ in Millions	Mar. 27, 2018office	Sep. 30, 2018USD ($)
Restructuring Cost and Reserve [Line Items]
Number of offices consolidated | office	2
Employee Termination | New Jersey Program
Restructuring Cost and Reserve [Line Items]
Employee termination costs		$ 1.5
Employee Termination | Sales Territory Program
Restructuring Cost and Reserve [Line Items]
Employee termination costs		$ 0.5